# Table of Contents

*Preface*  
xiii  
*Acknowledgments*  
 xv  

**1. Matter and Energy**  

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matter</td>
<td>1</td>
</tr>
<tr>
<td>Force</td>
<td>3</td>
</tr>
<tr>
<td>Energy</td>
<td>3</td>
</tr>
</tbody>
</table>

**2. Radiation and Its Properties**  

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Structure of an Atom</td>
<td>8</td>
</tr>
<tr>
<td>Subatomic Particles</td>
<td>10</td>
</tr>
<tr>
<td>Ionizing Radiation</td>
<td>11</td>
</tr>
<tr>
<td>Linear Energy Transfer</td>
<td>12</td>
</tr>
<tr>
<td>Electromagnetic Radiation</td>
<td>14</td>
</tr>
<tr>
<td>Wave-Particle Duality</td>
<td>15</td>
</tr>
<tr>
<td>Wavelength and Frequency</td>
<td>15</td>
</tr>
</tbody>
</table>

**3. The Production of X-Rays**  

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>The Discovery of X-Rays</td>
<td>19</td>
</tr>
<tr>
<td>Collision Interactions</td>
<td>20</td>
</tr>
<tr>
<td>Characteristic Radiation</td>
<td>22</td>
</tr>
<tr>
<td>Radiative Interactions (Bremsstrahlung)</td>
<td>24</td>
</tr>
<tr>
<td>Filters Used in Conventional X-Ray Therapy</td>
<td>26</td>
</tr>
</tbody>
</table>
## Table of Contents

Beam Direction as a Function of Incoming Electron Energy | 28
--- | ---
Beam Direction Dependency on X-Ray Target Design | 29

### 4. Radiation Quality | 33
- X-Ray Intensity | 33
- Beam Divergence | 34
- Beam Attenuation | 34
- Attenuation Coefficients | 41

### 5. X-Ray and γ-Ray Interactions with Matter | 45
- Attenuation Coefficients | 45
- Coherent Scatter | 47
- Photoelectric Effect | 48
- Compton Effect | 50
- Pair Production | 53
- Pair Annihilation | 55
- Photonuclear Interaction | 55
- Energy Absorption | 57

### 6. Principles of Radiation Detectors | 59
- Measurement of Radiation | 59
- Gas Ionization Detectors | 60
- How to Use a Survey Meter | 65
- Scintillation Detectors | 68
- Neutron Dosimeters | 69
- Thermoluminescent Dosimeters | 69
- Diode Detectors | 73
- MOSFET Detectors | 74

### 7. Determining Radiation Intensity | 77
- The Importance of Standardized Radiation Measurement | 78
- The Roentgen as a Unit of Exposure | 78
- Kerma | 79
- “Conventional” X-Ray Machine Calibrations | 80
- Radiation Absorbed Dose | 83
- The $f_{\text{medium}}$ Factor | 84
- Cavity Theory | 86
- Dose Equivalent | 88
# Table of Contents

8. Why Use Higher Energy Beams? 93
   - Disadvantages of Low-Energy Machines 94
   - Penumbra Size 95
   - Inability to Use Isocentric Techniques 97
   - Advantages of Megavoltage over Orthovoltage Beams 98
   - Skin Sparing 100
   - Electron Equilibrium 100
   - Disadvantages of Megavoltage 101

9. Linear Accelerators 103
   - Accelerator Guides 104
   - Waveguides 105
   - Power Sources 109
   - Bending Magnets 111
   - The Raw Electron Beam 115
   - X-Ray Beam Production 115
   - X-Ray Beam Flattening Filters 115
   - Photon Beam Collimation 118
   - Electron Beam Production 118
   - Electron Scattering Foils 119
   - Electron Beam Collimation 120
   - Monitor Chambers for Photon and Electron Beams 122
   - Helical Technology 123
   - The Linear Accelerator Console: The Operator Interface 124
   - Quality Assurance 124

10. Other High-Energy Machines 127
    - Cobalt-60 Machines (Radionuclide Teletherapy) 128
    - Timer Error 130
    - Penumbra 132
    - Quality Assurance of Cobalt-60 Machines 134
    - Cyclotrons 136
    - Heavy Particle Therapy 137

11. The Geometry of Photon Beams 141
    - Similar Triangles 142
    - Magnification 144
    - Abutting Fields 147
# Table of Contents

14. Treatment Planning 217
   - Tumor Targeting Vocabulary 218
   - Aims of Treatment Planning 218
   - What Treatment Planning Includes 220
   - Patient Alignment Devices 221
   - Patient Positioning Aids 222
   - Body Contours 222
   - Isodose Distributions 226
   - Oblique Incidence Corrections to Isodose Distributions 227
   - Isodose Summations 229
   - Treatment Techniques 230
   - Stationary or Fixed Beam Treatment 230
   - Moving Fields Treatment 233
   - Tissue Inhomogeneities 235
   - Tissue Compensation 238
   - Wedge Filters 240
   - Standard Treatment Calculation 244
   - Beam On Time Calculations (Timer Settings) 244
   - Monitor Unit Calculations 247

15. Clinical Applications in Treatment Planning 251
   - More Field Nomenclature 252
   - Mixed Beams 253
   - Tangents 256
   - Field Weighting 260
   - Normalization 260
   - Non-Coplanar Beams 265
   - Three-Dimensional Treatment Planning 267
   - Conformal Methods 268
   - IMRT 270
   - IGRT 272
   - Gated Radiation Therapy 272

16. Brachytherapy 277
   - Introduction 278
   - Radium 278
   - Radium Substitutes 278
   - Radioactive Sources 279
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicators</td>
</tr>
<tr>
<td>Afterloading</td>
</tr>
<tr>
<td>Single Plane, Double Plane, and Volume Implants</td>
</tr>
<tr>
<td>Permanent Implants</td>
</tr>
<tr>
<td>Implant Dosimetry</td>
</tr>
<tr>
<td>Remote High-Intensity Afterloading</td>
</tr>
<tr>
<td>Specific Implant Techniques</td>
</tr>
<tr>
<td>Radiation Safety with Implants</td>
</tr>
</tbody>
</table>

17. **Radiation Safety** 293

- Recommendations and Regulations 294
- Measurement of Occupational Radiation Dose 295
- Radiation Risk 296
- Maximum Permissible Dose Equivalents 302
- Personnel Monitoring 304
- Time, Distance, and Shielding 306
- Radioactive Materials 310
- Radiation-Producing Machines 316
- Signs 321

Appendix 1: Signs and Symbols 325
Appendix 2: Constants and Units 327
Appendix 3: Glossary 331
Appendix 4: Answers to Problems 343
Appendix 5: Dosimetry Tables 351
Appendix 6: Radioactive Nuclides 359
Appendix 7: The Elements 367
Periodic Table 372
Index 375
Preface

In this edition of *Applied Physics for Radiation Oncology*, the authors have tried to maintain the basic character of our earlier text as an introduction for radiation therapists. Most of the basic physics chapters remain unchanged, as the basic principles have not changed, and because of our belief that therapists should be taught physics principles to help them understand the technologies they apply to patients.

We have both expanded several chapters to add new techniques and removed some sections of only historic interest in others.

The collaborative team that produced this book includes those who helped produce previous versions including Rodger Holst, Joyce Keil, and Michael Nunno and a new contributor, Daniel Januseski, who updated the radiation safety chapter. We, the authors, guided the entire project and hope that our years of experience helped produce a textbook that is easy to read and helps students to learn.

Robert Stanton
Donna Stinson
September 2009
Treatment Planning

- Tumor Targeting Vocabulary
- Aims of Treatment Planning
- What Treatment Planning Includes
- Patient Alignment Devices
- Patient Positioning Aids
- Body Contours
- Isodose Distributions
- Oblique Incidence Corrections to Isodose Distributions
- Isodose Summations
- Treatment Techniques
- Stationary or Fixed Beam Treatment
- Moving Fields Treatment
- Tissue Inhomogeneities
- Tissue Compensation
- Wedge Filters
- Standard Treatment Calculation
- Beam On Time Calculations (Timer Settings)
- Monitor Unit Calculations

**Student Objectives**

1. List five types of target volumes and explain the importance of each.
2. Identify three aims of treatment planning.
3. Describe the process of: visualization, localization, and field selection and placement.
4. Describe field verification and documentation.
5. State the equations for timer and monitor unit calculations, and identify the type of equipment used for each.
Treatment planning is the process of determining the best method of treating a tumor with radiation. The major objective of treatment planning is to ensure that the tumor receives a uniform radiation dose while healthy tissue and critical structures are protected. Other important objectives of treatment planning are to develop reproducible setups and maintain patient comfort.

Treatment planning includes determining the volume to be treated and then designing appropriate radiation fields to treat that volume. It begins before the first radiation treatment and continues throughout a course of therapy to ensure that the intended plan is being implemented. A treatment plan may sometimes be changed during a course of therapy to compensate for changes in a patient’s condition.

Professionals from several areas work together in developing the best treatment plan for each patient. These professionals include radiation oncologists, physicists, treatment planners (dosimetrists), and radiation therapists.

**TUMOR TARGETING VOCABULARY**

All of the individuals involved need to use the same vocabulary when discussing and planning patient treatment. Tumor dose (TD, or prescribed dose, $D_{Re}$) is the dose to be delivered to the disease being treated. The patient “work-up,” defines the gross tumor volume (GTV), the palpable or visible extent of tissue that makes up the tumor. The clinical target volume (CTV) is the gross tumor plus a margin to include any areas of direct but subclinical disease spread. During the process of treatment planning, the planning target volume (PTV) is determined. It includes the clinical target volume plus the needed margin to ensure delivery of dose to the target when motion, setup variations, etc. are taken into account. Determining the tumor and target volumes are two of the key clinical decisions of the radiation oncologist. Once the treatment plan is developed, two other volumes can be determined. Treated volume (TV) is the volume of tissue that actually receives the tumor dose; it may be larger but should not be smaller than the clinical target volume. The irradiated volume is the entire volume of tissue hit by any portion of the radiation aimed at the tumor that receives a significant absorbed dose. See figure 14.1 for illustration.

**AIMS OF TREATMENT PLANNING**

Treatment planning is often a challenging process during which teamwork is required to achieve optimal and reproducible radiation treatments.
There are three aims of treatment planning:

- Develop a plan that treats the tumor volume. This plan should give as homogeneous a dose distribution as possible throughout the clinical target volume.
- Minimize radiation dose to healthy structures. Areas outside the target volume should receive as little radiation as possible. Limiting dose to healthy tissues requires knowledge of how much radiation the tissues in the treatment field can tolerate. Dose levels to critical structures such as the spinal cord, kidneys, and the lens of the eyes must be minimized.
- Provide a permanent record of dose calculations and distributions so that others may, in the future, understand the treatment plan. This permanent record is not just the computer printout of a dose distribution; it includes the prescription, diagrams of the treatment field, tattoo identification, simulation and portal films, as well as other computations performed before, during, and even after each course of treatment. This record may become important if the patient needs to receive more radiation in the future.
WHAT TREATMENT PLANNING INCLUDES

Treatment planning includes visualization, localization, field selection and placement, and verification.

**Visualization** is the determination of the location and extent of the tumor, particularly with respect to anatomical landmarks. This process uses every reasonable method of examination, including palpation, radiography, or radiographic imaging (CT, PET-CT, MR, ultrasound, mammograms, etc.) and, when possible, direct visual examination. All the information gathered in these various examinations is correlated by the radiation oncologist, who uses it to define the volume to be treated in each patient. **Fusion** techniques may be used to combine images from more than one modality. When technology is used to overlay a diagnostic image, such as a PET-CT, with a treatment planning image, the images are described as fused.

**Localization**, or **simulation**, is the radiographic determination of the field borders required to encompass the clinical target volume. Ideally, localization is performed using a **simulator**—radiographic (imaging) unit that simulates all the movements of the linear accelerator or Cobalt-60 treatment unit and matches its geometry, distances (SSD, SDD, etc.), beam divergence, and field size. A simulator produces high-quality images of the treatment field.

During simulation, the patient is placed in as comfortable a position as is consistent with good beam placement. Accurate, reproducible positioning is critical since positioning during localization is almost always the position the patient must maintain throughout the course of treatment. During traditional radiographic localization, **orthogonal images** (those taken at right angles to each other) are frequently taken so that all three dimensions (x, y, and z planes) of a patient’s anatomy can be documented. Sometimes these orthogonal beams are actually used for treatment. Other times they are used solely as a step in tumor localization.

CT-simulation has largely replaced radiographic simulation. **Digitally reconstructed images (DRR)** are produced by using data acquired by the CT in the axial plane and translated to another plane (i.e., sagittal plane).

**Cone beam CT (CBCT)** is a technique that uses electronic portal imaging associated with modern linear accelerators. The megavoltage energy of the accelerator, along with an amorphous silicon flat panel, is used to reconstruct an axial image. These images are used to document accuracy of treatment plans at the initiation of therapy and/or as a method to monitor anatomy, including tumor size, throughout a course of therapy.

The next step is **field selection and placement**. The treatment planner selects various field sizes and beam placements to irradiate the specific tumor volumes. The dose contributions to the target as well as other organs are evaluated.
by the planner and used to choose the best combinations of beams. The chosen plan is then documented, listing the dose contributions to all important structures.

The final step in treatment planning is verification. The goal of verification is to ensure that the volumes planned for treatment are actually the areas being treated. This takes place on the actual treatment unit. Prior to the first treatment, radiographic documentation of the treatment field is necessary. Radiographic films, known as portal images, are made with electronic methods, or with film and/or cassettes designed for high-energy exposure. Film-holding cassettes often include a metal screen that produces electrons through high-energy photon interaction. These compton electrons help produce the radiographic image. Although portal films are of poorer overall image quality than other radiographic images, they contain sufficient information to determine the accuracy of beam placement.

Verification images are often repeated on a weekly basis during each patient’s treatment course to ensure continued correct field placement. New electronic portal imaging devices, similar in function to x-ray fluoroscopes, are also used for this purpose.

Documentation is critical throughout every step of treatment planning. All the data derived from visualization, localization, field selection and placement, and dosimetry calculations must be precisely recorded. Complete and accurate documentation of the details of each treatment is required so that accuracy and consistency, which directly influence the success of every patient’s course of therapy, are maintained.

**Patient Alignment Devices**

To achieve accurate alignment of the radiation fields on the patient several devices are used.

**Field lights** are the most essential beam alignment devices, because the light field on a therapy machine corresponds geometrically to the radiation field to an accuracy of ±3 mm. Tattoos and field edge marks on the patient are aligned with this light field before each treatment.

The **protractor**, or gantry angle indicator, is another alignment device. Just as every beam has a particular size that is defined by the field light, there is a particular gantry angle that is read on the machine protractor. This is read either mechanically or from a digital readout.

**Lasers** are commonly used as positioning aids but are not actually part of the treatment machine. There should be at least one laser on each side of the patient (referred to as lateral or side lasers) and one pointing down at the machine isocenter from the ceiling (referred to as an overhead laser). A sagittal laser also
projects a straight line and points toward the isocenter along the longitudinal axis of the patient or table. Lasers are used in daily patient setup, and their alignment should be checked daily as a part of the quality assurance program. Daily alignment of lasers ensures reproducible and accurate positioning.

**Back pointers** are mechanical devices that, when mounted on the gantry, point to the exit point of the beam’s central ray; that is, they indicate the position at which the radiation will exit the patient. Historically, back pointers were particularly useful in positioning parallel opposed tangential fields, e.g., for breast treatments, but have been replaced by laser positioning technology in the modern treatment environment.

### Patient Positioning Aids

Once the location of the tumor is ensured and the patient has undergone the simulation process, it is necessary to position the patient accurately every day in the same treatment position. The use of patient positioning aids helps the patient maintain the proper treatment position without sacrificing comfort.

Many such devices are available. One of the most simple is adhesive tape used in conjunction with specially contoured head holders for head and neck treatments.

Better precision in positioning is achieved with individual **bite blocks** (custom mouthpieces). These are devices with calibrated bars and support arms attached to the patient using a custom mouthpiece, as shown in figure 14.2. When the patient is positioned, he or she bites down on the bite block, positioning his or her head and neck rigidly in the correct position.

There are several other patient positioning devices used. Specially cast patient supports made of plaster, thermal plastic materials, or cast Styrofoam materials can be used to make rigid supports for the patient. See figure 14.3. For most accurate treatment, these positioning devices should be fabricated before simulation so that the patient is in an identical position throughout the whole planning and treatment process.

### Body Contours

A **body contour** is a precise outline of a patient, usually in a transverse plane that includes the region of the tumor. A contour is required both for computing and for displaying the dose distribution in the treatment volume. Frequently done at the time of localization, a contour is usually taken at the central axis plane of the fields but may be taken at other levels as well to evaluate the dose distribution.
Figure 14.2
Bite block device (custom mouthpiece). A contoured headrest is fixed in position in a calibrated and adjustable holder. Each patient has an individual mouthpiece that fits into this device. When all of the settings on the device are matched with those determined at simulation, the patient position exactly reproduces that held during simulation.

Figure 14.3
Patient in Alpha Cradle immobilization device. The patient, once placed in this custom formed device, is held in a reproducible position for daily treatments. Photograph reproduced with permission from Smithers Medical Products, Inc., North Canton, Ohio.
There are several ways of **contouring** a patient, i.e., determining the patient’s shape quantitatively. The best method to use is a CT scan, because it provides richly detailed information about external and internal anatomy. This method gives a three-dimensional rendering of the patient outline, allowing three-dimensional treatment planning with much freedom in the choice of radiation beam orientations. However, due to the small opening of most CT scanners (which usually ranges from 60 to 80 cm), CT scans are not always helpful in indicating the actual treatment position (especially in a breast setup). Large bore CT scanners help to resolve this issue.

A less commonly used and less expensive method of contouring is plaster of Paris bandage material. A strip of bandage at least four layers thick is wet completely, squeezed out, and then placed over the patient in all areas through the central axis plane of all the radiation fields to be used. While the plaster dries (which takes several minutes), the exact locations of portals and other important information such as name, date, and patient dimensions through beam centers are recorded on the contour itself and/or on an accompanying record.

Other means of contouring a patient include using ultrasound devices, lead solder wire, and special devices constructed of movable rods that take on the shape of the object against which they are pressed.

Contour types include **sagittal**, **coronal**, and **transverse** plane; figure 14.4 illustrates these planes. These three types of contours provide the three dimensions of the patient’s body.

The diameters of the patient are documented. These diameters are called **interfield distances (IFD)**, or **separations**.

Regardless of the method selected, precise contouring is a critical part of good treatment planning.

After contouring, the shape is transferred to paper and a cross section of the **planning target volume** as described earlier is drawn on the paper by either the radiation oncologist or the dosimetrist from films marked by the radiation oncologist. This method of transferring data, however, is being replaced by the direct reading of CT images into the treatment planning system. As CT becomes more widely available in radiation oncology centers, the direct reading of CT images into the treatment planning system is becoming more common.

Contour placement on paper includes carefully measured patient dimensions, marks corresponding to simulation film field centers, and comments on patient positioning. The accuracy of the patient contour is critical, because misregistering of the beam center could lead to errors in the positioning of internal organs or the beams themselves. The treatment planner must clearly understand the physician’s prescription. A 1 cm error in depth could result in a 75% error in dose using electron beams, a 15% error in dose with low-energy photon beams, and a 5% error in dose with megavoltage photon beams.
Figure 14.4
a) Transverse contour of abdomen.
b) The three planes in which contours are taken and their positions on the body.
ISODOSE DISTRIBUTIONS

Isodose charts are families of isodose curves, usually drawn for equal increments of percent depth dose (%DD or PDD). The curves represent the lines of equal DD for a particular field size and SSD at a specific plane in tissue. They are different for different beams, showing the effect on dose distribution due to energy, source size, SSD, and beam attenuation.

Figure 14.5 shows a 6 MV beam isodose distribution. Two points are shown on the distribution, P and Q. The point P corresponds to a dose of 90%, and the point Q to a dose of about 75%. Note that the depths on the central ray of various DD values, e.g., 90%, 80%, etc., increase as the percent DD decreases. Also, note that as you move to the edge of the beam at a specific depth, the DD drops. In other words, the isodose curves bend toward the skin surface as you move to the edge of the beam. This drop in DD values at the edge of the beam is due to the fact that there are fewer scattered photons at the edge than at the center. In the center of the beam, scatter can come from both sides; at the edge, it can come only from one side.

Figure 14.5
Isodose curves for a 6 MV linear accelerator beam. Note the points labeled P and Q. They are located at percent depth dose levels of 90% and 75% respectively.
In figure 14.6, the distribution on the left is for a 200 kV beam, 1.5 mm Cu HVL, a 50 cm SSD, and a 5 cm \times 7 cm field. The middle distribution is for a 6 cm \times 6 cm field of a $^{60}$Co beam at 80 cm SSD. The distribution on the right is for a 25 MV beam with a 6 cm \times 6 cm field size at 100 cm SSD. Note that the depth of a particular isodose line increases with increasing photon energy. The shape of the isodose lines at the edge of the beam is also noteworthy. The $^{60}$Co beam, which has a larger source size, has a much larger penumbra than the megavoltage x-ray beam. This is apparent when you compare the greater separation of the isodose lines at the beam edges.

**Oblique Incidence Corrections to Isodose Distributions**

In the previous discussion it was assumed that the radiation fields struck the patient perpendicular to the skin surface and that the patient’s tissue was homogeneous.

![Figure 14.6](image)

**Figure 14.6**

Comparison of isodose lines for various energies. The left set of curves is an orthovoltage beam. Each curve has rounded edges and the low percentiles bow outward. The middle set of curves is for a $^{60}$Co beam. Note that its isodose lines are flatter and penetrate more deeply. The right set of curves is for a high-energy photon accelerator beam. Note the deep penetration of the isodose lines and the tightly packed nature of the lines at the beam’s edge. (Reprinted from Johns & Cunningham, *The Physics of Radiology*, 4th edition, 1983. Courtesy of Charles C Thomas Publisher, Ltd., Springfield, Illinois.)
These conditions are reflected in standard isodose lines, which are measured under the ideal conditions of the radiation beam striking a flat water surface at right angles.

Of course, patients have curved surfaces and tissue inhomogeneities like bones and lungs. Most treatment planning systems correct for these inhomogeneities using calculation algorithms such as tissue-air ratio corrections and effective attenuation corrections.

These corrections are made by computer; however, in order to appreciate the benefits of computerized corrections, we will demonstrate a manual calculation method. In this approach, standard isodose lines are modified in order to approximate the clinical situation. This is known as the isodose shift, or 2/3 or 1/2 shift technique. It is a useful method for compensating for too little or too much tissue along the patient contour; see figure 14.7.

Shifting corrects the standard isodose lines by applying correction factors in the form of moving the isodose lines by a fixed portion of the tissue difference. (The standard isodose lines are obtained with the radiation beam entering perpendicular to a flat surface.) The portion chosen for the shift factors is a function of the beam energy and the machine SAD. The values of shift are shown in table 14.1.

In table 14.1, the shift factor decreases with increasing energy because of two effects: inverse square law and tissue attenuation. High-energy machines have larger SADs than low-energy machines (e.g., 60Co and orthovoltage units). The larger distances reduce the drop-off of dose with distance. In addition, the higher the energy, the less attenuation by tissue. Figure 14.7 shows the curved surface of a patient contour with a straight line corresponding to the SSD at the central axis. A thick line shows a standard isodose curve. The corrected isodose line for the actual contour is formed by moving the standard curve by the appropriate fraction of the distance between the actual contour and the straight line. The direction of the “shift” is away from the tissue deficit and toward the tissue surplus. In figure 14.7 we see the effect of skin contour on an isodose line of a single field. This means that the level of d_{max} follows the skin surface.

<table>
<thead>
<tr>
<th>Machine Energy</th>
<th>Isodose Shift Factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>150 kV-1 MV</td>
<td>0.8</td>
</tr>
<tr>
<td>1-5 MV</td>
<td>0.7</td>
</tr>
<tr>
<td>Cobalt-60</td>
<td>0.75</td>
</tr>
<tr>
<td>5-15 MV</td>
<td>0.6</td>
</tr>
<tr>
<td>15-30 MV</td>
<td>0.5</td>
</tr>
<tr>
<td>30 MV</td>
<td>0.4</td>
</tr>
</tbody>
</table>
One important practical effect of non-perpendicular beam incidence is on skin sparing. In some clinical situations the beam strikes the skin surface tangentially (e.g., breast tangents). In this case, the $d_{\text{max}}$ depth is reduced significantly, reducing skin sparing and producing more skin erythema and other skin reactions as well.

**ISODOSE SUMMATIONS**

When more than one field is used, the isodose curves of all fields must be added together to produce an isodose summation. Summations are usually produced using computers but can also be done (tediously) by hand. The manual summation process will be discussed using the example of two parallel opposed fields as illustrated later in figure 14.8.

The first step in summing two parallel opposed beams is to trace the isodose curves for each single field separately onto the contour. It helps to use two colors. When the lines of two isodose sets intersect, the percentages of those crossing isodose lines are added together. This result is called the summated percentage. This process is repeated at enough overlapping points to get a collection of summated percentages that sufficiently describe the summated distribution.
Computers do this process as a geometrical array of points or grid in the calculation plane thousands of times faster than the manual process. See reference 1 in chapter 6 for more information on the manual process. Chapter 15 will describe the alternative ways for describing the resulting distributions.

Figure 14.8 shows the summated isodose distribution of two parallel opposing fields. Note the hourglass shape of the highest isodose line; the hourglass shape is reduced as the beam energy increases.

**TREATMENT TECHNIQUES**

There are many ways of using external beam therapy to treat tumors. In stationary, or fixed beam, treatment the patient is positioned on the treatment couch and then irradiated by fields directed at the treatment volume at one specific gantry angle. These fields can be set up as either SSD or SAD (isocentric).

![Figure 14.8](image)

*Figure 14.8*

Parallel opposed x-ray fields used to treat a centrally located lesion. The hourglass shape of the high-percentage isodose curve is due to the effects of penumbra and scatter of each beam.
Stationary or Fixed Beam Treatment

Figure 14.8 illustrates the isodose distribution for the parallel opposed field (POF) beam configuration. Note the characteristic hourglass shape of the highest intensity isodose line, where it pinches in or narrows at the midline. This application of fields is suited to treatment of midline structures. A uniform dose (±5-10%) is given to a very large volume from $d_{\text{max}}$ on the entrance of the AP field all the way to the $d_{\text{max}}$ on the entrance of the PA field. While good for large lesions or central tumors including more superficial nodal areas, this distribution is not optimum.

Figure 14.9
Three-field isodose distribution. Note in this distribution of three 6 MV beams with 100 cm SAD that the 100% dose value is centrally located (at the isocenter), and the 90% line surrounds the treatment volume. With lower energy beams there are often “hot spots,” areas of high dose (90%) at the entrance region of the beams.
when midline structures are treated behind sensitive structures like the spinal cord. The addition of other beams can reduce the relative dose to superficial tissues while maintaining a high central dose. Whenever another beam is added, the isodose lines are pulled in the direction of that new beam. Figure 14.9 shows the effect of a three-field plan on the isodose distribution.

One very common treatment plan for bladder, rectum, and prostate cancer uses two sets of parallel opposed fields, four fields at right angles aimed at the same center. The resulting isodose distribution is box-like; this treatment approach is therefore called a four-field box technique. Such an approach is shown in figure 14.10 for a 18 MV machine at 100 cm SAD. The summation of the four fields’ dose lines produces a uniform distribution in the center and results in lower entrance doses with the box technique than with parallel opposing fields. In effect, the more fields used, the higher the central dose relative to the entrance doses.
A variation of this technique is sometimes used. The **four-field diamond** is shown in figure 14.11. This configuration of beams lowers the dose at the sides of the patient. In pelvis treatments, for example, this means that the femoral head and rectal doses are less. The choice of beam combinations is dependent on the shape of the target volume, the type of tissues adjacent to that volume, the patient’s size, and the beam energies available.

### Moving Fields Treatment

The ultimate approach to adding fields that limit superficial doses is moving the beam during treatment. Such fields are called **moving, or dynamic**, fields. In this type of treatment, the patient lies at rest on the linear accelerator couch, and
Rotational therapy is when the beam makes a complete $360^\circ$ rotation around the patient. If the beam makes less than a full rotation, it is called arc therapy. The word rotation is often used for any moving field technique, either full rotation or arc therapy. Double or multiple arc therapy is when two or more arcs are used. Skip arc therapy is when the beam is turned off for specific segments of the rotation. In most rotational therapy, the center of the tumor is placed at the isocenter of the machine. Therefore, the SSD varies continuously as the machine rotates.

Figure 14.12 illustrates the isodose distribution for a $360^\circ$ rotation of a 7 cm $\times$ 9 cm field size at 80 cm SAD with a 4 MV beam. Note that the isodose lines are circular in shape at the high percentiles, while the lower percentiles are more oval in shape with the long axis of the oval at right angles to the width of the patient. If the patient were shaped like a circle, all of the isodose lines would be circles. Also note that, with the full rotation technique, the isodose lines are centered on the machine isocenter.
When partial rotations are used, the maximum dose always occurs towards the machine head. That is, if the radiation beam arcs over the anterior part of the patient, the dose will lie mostly in the anterior portion of the patient. Figure 14.13 demonstrates the isodose distribution for a 180° anterior arc. It shows that in a partial rotation treatment, the isocenter should be placed a few centimeters posterior to the tumor center. This is called past pointing. In this technique, the isocenter of the machine is placed behind the target volume and the beam is aimed from in front of the lesion. By placing the isocenter of rotation past the tumor center, the dose distribution is effectively pulled in a manner that covers the tumor volume as shown in figure 14.13.

**Tissue Inhomogeneities**

Tissue inhomogeneities are volumes within the patient that have non-uniform tissue densities. For example, while the density of most soft tissue is about 1, that
of lung is much lower, bone somewhat above 1, and metal plates used in bone repair much greater than 1. Tissue inhomogeneities alter the dose distribution from the standard curves due to attenuation and scatter. Calculations to account for these inhomogeneities, heterogeneity corrections, inside the patient are handled in a similar fashion to oblique incidence (discussed earlier). Instead of shifting 1/2 or 2/3 in the direction of tissue deficit, the curves shift away from the patient surface (deeper) with low-density inhomogeneities (e.g., air cavities) or toward the patient surface with high-density inhomogeneities (e.g., bones). Table 14.2 illustrates factors used for various tissue corrections.

Other approaches to tissue inhomogeneities are also possible. One method for correcting tissue inhomogeneities is the effective TAR method. It is a point-by-point calculation technique instead of a line-by-line technique and is therefore appropriate only for computerized point calculations. For each point in the patient (actually each point of interest) the equivalent water path length or depth is calculated using electron densities of overlying tissues. Imagine that the patient contour is filled with a matrix of calculation points and that the computer calculates doses at each of the matrix points. See figure 14.14.

Figure 14.15 illustrates the effective TAR computation process using only three points. The three points on the right of the phantom (P1, P2, and P3) are traversed by the x-ray beam from the left. To reach the three points, however, the radiation beam has to travel through three different materials—air, water, and bone.

In order to calculate the appropriate TAR for each material, the water equivalent path length must be determined. This is the thickness of water that will provide the identical attenuation of the actual beam path.

The calculation for P1 is as follows:

\[
\text{Path length } P_1 = 5 \text{ cm water} + 6 \text{ cm air} + 5 \text{ cm water} \\
= 10 \text{ cm water} + 6 \text{ cm air} \\
= 10 \text{ cm water}
\]

### Table 14.2 Isodose Shift Factors for Tissue

<table>
<thead>
<tr>
<th>Inhomogeneity</th>
<th>Isodose Shift Factor*</th>
</tr>
</thead>
<tbody>
<tr>
<td>air cavity</td>
<td>0.6</td>
</tr>
<tr>
<td>lung</td>
<td>0.4</td>
</tr>
<tr>
<td>hard bone</td>
<td>-0.5</td>
</tr>
<tr>
<td>spongy bone</td>
<td>-0.25</td>
</tr>
</tbody>
</table>

*Positive—shift isodose curves deeper in the body.
Negative—shift isodose curves toward the skin.
Because of its low density, 6 cm of air is equivalent to less than 1 mm of water and is ignored. Therefore, the equivalent length is just 10 cm.

The calculation for $P_2$ is handled similarly:

\[
\text{Path length } P_2 = 5 \text{ cm water} + 6 \text{ cm water} + 5 \text{ cm water} = 16 \text{ cm water}
\]

---

**Figure 14.14**
Computer view of a patient is actually a set of points in space surrounded by attenuating material. Each point lies in a rectangular array of points, a matrix of calculation points at which individually computed doses are produced.

Because of its low density, 6 cm of air is equivalent to less than 1 mm of water and is ignored. Therefore, the equivalent length is just 10 cm.

The calculation for $P_2$ is handled similarly:

\[
\text{Path length } P_2 = 5 \text{ cm water} + 6 \text{ cm water} + 5 \text{ cm water} = 16 \text{ cm water}
\]

---

**Figure 14.15**
Effective TAR example. This figure illustrates the TAR computation process involved, using only three points. Points $P_1$, $P_2$, and $P_3$ are behind three different materials—air, water, and bone. The air supplies less attenuation than the water, while the bone supplies more. Note that the air cavity and bone are surrounded by water.
and for $P_3$,

$$Path\ length\ P_3 = 5\ cm\ \text{water} + 6\ cm\ \text{bone} + 5\ cm\ \text{water}$$

$$= 10\ cm\ \text{water} + 6\ cm\ \text{bone} \left(\frac{\text{bone\ density}}{\text{water\ density}}\right)$$

$$= 10\ cm\ \text{water} + 6\ cm\ \text{bone} \left(\frac{1.5\ g/cm^3}{1.0\ g/cm^3}\right)$$

$$= 19\ cm\ \text{water}.$$

Thus the dose at $P_1 > dose at P_2 > dose at P_3$. In this equation, bone density (1.5 g/cm³, i.e., 1.5 times the density of water) is used to convert the bone thickness to water thickness. Once the path length for a point is calculated, it is used as the depth to determine the TAR (by looking it up in the TAR tables) for the point in question.

Both equivalent path length and isodose shift are only approximation methods. They do not account for scatter from different nearby structures, but give answers good to within a few percent. They have been presented here to demonstrate some of the considerations of isodose construction.

**Tissue Compensation**

Another way of correcting doses in cases of tissue deficit is to make the surface flat using tissue equivalent material called bolus (see figure 14.16). Materials used for bolus include rice, sugar pellets, flour, sodium bicarbonate, and other various mixtures.

Bolus may also be used to bring $d_{\text{max}}$ to the patient’s skin surface. In these cases, materials such as wet gauze, Vaseline gauze, or other malleable tissue equivalent materials are used in a thickness equal or close to that required for the production of electron equilibrium.

When bolus is used, SSD in both patient setup and treatment planning must be consistent. If the dosimetrist calculates using 100 cm SSD to the bolus (101.5 cm SSD to the surface with 1.5 cm $d_{\text{max}}$ for a 6 MV photon beam) and if the therapist uses 100 cm SSD to the skin (98.5 SSD to the bolus), an error as large as 3% can be introduced into the patient treatment.

The placement of bolus on the skin surface reduces skin sparing in megavoltage photon beams as described in chapter 8. Custom-shaped compensating filters (see figure 14.17) are sometimes used to avoid this bolus effect. The distance between the compensator and the skin surface is large enough (at least
Figure 14.16
Tissue deficit compensation. In this example, the hatched area at depth is to be treated. The air gap shown on the left (a) causes an uneven dose distribution over the tumor and can be compensated for by using either of two approaches. The first is bolus (b), where the compensation material is in contact with the patient. One unfortunate consequence of bolus is the loss of skin sparing. Effectively moving the bolus from the patient surface toward the machine source (blocking tray position) retains the compensation of the bolus while re-establishing skin sparing (c and d). (Reprinted from Johns & Cunningham, *The Physics of Radiology*, 4th edition, 1983. Courtesy of Charles C Thomas Publisher, Ltd., Springfield, Illinois.)

Figure 14.17
Geometry of tissue compensating filters. The compensators are placed in a holder near the photon source and mimic the shape of the patient's inhomogeneities. Because of beam divergence, the compensator is smaller than the bolus it replaces.
15 cm) to disperse electron and photon scatter produced in the filter, thereby re-establishing skin sparing. These filters are made of brass (only used with low-energy photons), aluminum, lead, leaded plastics, or Cerrobend and are shaped to have the same effect at depth in the patient as the more simple bolus. Because of the loss of side scatter from compensators, they are generally thinner in mass-length than the tissues they replace. Recently, computer-controlled milling machines have been adapted to create customized tissue compensators out of composite lead and plastic mixtures and other materials. Compensators are used most often in lung, head, and neck treatments.

**Wedge Filters**

A common, non-customized compensating device is the **wedge filter**, or **wedge**, shown in figure 14.18. A wedge is used to distort the isodose distribution by tilting isodose lines through a specific angle (figure 14.19). Wedges are sometimes used to compensate for sloping body surfaces. They are also used to good effect for areas of great obliquity such as neck, breast tangents, and other anatomic areas where **hot spots** (regions of maximum dose occurrence) could occur (shown later in figure 14.21). The thick end of the wedge is called the **heel** (which transmits less of the initial beam) and the thin end the **toe** (which transmits more of the initial beam).

The angle to which a specific isodose line is bent is also the name of the wedge and is called the **wedge angle**. Lower energy machines use a 50% or 60% isodose line, while higher energy machines use 70% or 80%. Wedges are available for all megavoltage treatment machines at specific angles, usually 15°, 30°, 45°, and 60°.

A slightly different approach is used by some manufacturers who use one single wedge permanently mounted in a motorized moving tray within the machine head. By varying the proportion of the mu setting that the wedge is in the beam, you can vary the effective **wedge angle**. Some manufacturers call this a **universal wedge**. This approach can also be used with conventional wedge sets in order to create effective wedge angles of any angle by mixing open and wedged beams.

---

1. In the 1950s through the 1970s, the term universal wedge was used in a different context, referring to a wedge of a specific angle designed for use for all field sizes (with its center always on the beam axis) instead of for a specific field size. In these individualized wedges, the toe was always aligned with the beam edge. This usage of the word “universal” is no longer common.
Figure 14.18
Wedge vocabulary. Wedges are usually made of high Z materials to minimize space needed in the machine head or above the blocking tray holder.

Figure 14.19
An isodose chart for a 10 cm × 10 cm field size, 6 MV x-ray beam, used with a 45° wedge.
Another approach is used by most new linear accelerators. In these units, the independently variable jaws are moved during the therapy treatment, producing the effective dose distribution of a standard wedge but without the use of any wedge filter. This approach is sometimes called dynamic or virtual wedge.²

2. Before moving jaw dynamic wedges became common, the internal wedges described above were sometimes called dynamic wedges.

Figure 14.20
The hinge angle is the angle between the central rays of the two beams.

Figure 14.21
A pair of unwedged fields at 90° angles. Note the hot spot (H) where the beams overlap in the area of tissue deficit.
Wedged fields are often used in pairs, called **wedge pairs**. The angle between the two fields is dictated by patient anatomy and is called the **hinge angle** (figure 14.20). Then the following simple formula is used to predict the appropriate wedge angle to use for the optimal dose distribution:

\[
\text{Wedge angle} = 90^\circ - (0.5 \cdot \text{hinge angle})
\]

or:

\[
\text{Hinge angle} = 180^\circ - (2 \cdot \text{wedge angle})
\]

Thus, 45° wedged fields usually have a 90° hinge angle. Similarly, 60° wedged fields usually have a 60° hinge angle.

Figures 14.21 and 14.22 demonstrate the use of wedges on a maxillary sinus tumor. The first figure shows two beams aimed at a structure at right angles without wedges. With the insertion of 45° wedges with their heels toward each other, the dose uniformity over the tumor is markedly improved.

Wedges are used frequently in tangential breast, three-field pelvic, and numerous other field irradiation arrangements. Some of these will be discussed in greater detail in chapter 15.

Figure 14.22
Wedged pair distribution. Note that the hot region shown in figure 14.21 is eliminated by attenuation of the beam by the thick end (heel) of the wedge.
STANDARD TREATMENT CALCULATION

The final step in any treatment plan is the calculation of treatment time or monitor unit setting for the energy being used. The basic physics of this process is discussed in chapter 12 along with specific equations. This section demonstrates some of these techniques.

BEAM ON TIME CALCULATIONS (TIMER SETTINGS)

Machines such as $^{60}$Co units, orthovoltage, and superficial x-ray machines are controlled using a timer setting. The technique for time calculation will be demonstrated in two steps. First, the general approach to the problem will be outlined. Second, a numerical orthovoltage example will be presented.

Surface lesions are often treated using fixed cones that are larger than the tumor to encompass both the lesion and an adequate margin. In these cases, lead masks or cutouts are used to shield all but the desired area. The thickness of lead necessary is usually $1/8''$ (3.2 mm) or less. For example, the skin of a patient is treated to the area shown in figure 14.23. The rectangular area has an equivalent square field size of $2 \text{ cm} \times 3 \text{ cm}$ or $2.4 \text{ cm}^2$ as determined from the equivalent squares in table 12.1.

Figure 14.23
Lead cutout in a 5 cm $\times$ 5 cm field. The hatched area is covered by lead, leaving an open area with an effective field size of $2 \text{ cm} \times 3 \text{ cm}$.
There are three steps involved in calculating the timer setting for a treatment. The first step is the determination of dose rate. Its value is determined from the results of the machine calibration combined with other data on the beam as follows:

\[
\text{Dose rate} = \text{Machine output} \times f_{\text{med}} \times \text{BSF},
\]

Here, machine output is obtained at the time of annual calibrations, usually determined for the unblocked cone when using superficial and orthovoltage beams, and/or the open field when using 60Co beams. The \( f_{\text{med}} \) value (R to cGy conversion factor) is determined from tables, such as table 7.3, and the value of BSF is obtained from table 14.3 for the specific quality of the beam, which is measured at the time of machine calibration, or appendix 5 for 60Co. Second, once the dose rate is determined, the beam on time can be obtained using the simple equation:

\[
\text{Beam on time (min)} = \frac{\text{Dose per fraction}}{\text{Dose rate}}
\]

where the numerator indicates the dose per fraction in cGy and the denominator indicates the rate, which is the actual number of cGy per minute (or for orthovoltage units, R/min) at the skin.

Third, we measure the timer error (discussed in chapter 10), which is determined at the time of machine calibration. While timer errors for superficial beams are usually negligible, orthovoltage beams and 60Co machines may have significant timer errors. Beam on time is determined using the simple equation:

\[
\text{Timer setting} = \text{Beam on time (min)} + \text{Timer error}
\]
As a numerical example, we are given the following calibration information:

Output of 5 cm square cone: 90.3 R/min  
kVp: 220  
Filter: 0.75 mm Cu  
HVL: 1 mm Cu  
Timer Error: + 1.5 seconds  
Prescription: 300 cGy per fraction

Now we are asked to determine the timer setting to deliver 300 cGy to the patient’s skin. From table 12.1, the effective field size is 2.4 cm. That means the dose rate at the skin is as follows:

\[ \text{Dose Rate} = \text{Machine output (open cone)} \cdot f_{\text{med}} \cdot \text{BSF (blocked field)} \]
\[ = 90.3 \text{ R/min} \cdot 0.95 \text{ cGy/R} \cdot 1.11 \]
\[ = 95.2 \text{ cGy/min}. \]

Note that the BSF is determined for the open area of 2 cm \( \times \) 3 cm (2.4 cm equivalent square field size). The value 1.11 is interpolated from table 14.3). The beam on time necessary for the treatment is:

\[ \text{Beam on time (min)} = \frac{\text{Dose per fraction}}{\text{Dose rate}} \]
\[ = \frac{300 \text{ cGy}}{952 \text{ cGy/min}} \]
\[ = 3.15 \text{ min}. \]

Finally, to determine timer setting, we first convert the decimal minutes to seconds before adding in the timer error as follows.

\[ \text{Timer Setting} = \text{Beam on time} + \text{Timer error} \]
\[ = 3' 9" + 1.5" \]
\[ = 3' 11" \]

This example demonstrates the technique for use in a roughly rectangular field. If the field is more circular, the equivalent field size can be determined using techniques outlined in BJR Supplement 25 (reference 3). This same technique is also used for superficial x-ray machine treatments and is similar to that for \(^{60}\text{Co}\) machines.
**Monitor Unit Calculations**

In linear accelerators, dose delivery is controlled by selecting the number of monitor units (mus). Therefore, there is no timer error and the formulas for dose calculations are different than those for machines that use timer setting. Two examples will illustrate the approach.

**Example 1**: A patient is treated to the sacrum through a single PA field to deliver 300 cGy at a depth of 6 cm using a 4 MV linac. SSD = 80 cm and the field size is 10 cm \( \times \) 15 cm using a small corner block on a plastic tray. As described in chapter 12, the equation is:

\[
N_{\text{mu}} = \frac{\text{Tumor dose}}{C_{\text{cal}} \cdot C_{f_s} \cdot C_{\text{sem}} \cdot DD}.
\]

The appropriate values for these factors are determined as previously outlined. The 10 cm \( \times \) 15 cm field size has an equivalent square of 11.9 cm\(^2\). The field size factor is determined from figure 12.4 and is 1.02. The attenuation of the tray is 0.96. The depth dose is 0.783, which is determined from appendix 5, table 2. The resulting mu setting is therefore:

\[
N_{\text{mu}} = \frac{300 \text{ cGy}}{10 \text{ cGy/mu} \cdot 1.02 \cdot 0.96 \cdot 0.783} = 391.
\]

**Example 2**: A more complicated treatment is a pair of parallel opposed 6 MV fields to treat a patient’s pelvis. The field size is 20 cm \( \times \) 12 cm, the patient thickness is 20 cm, and the patient is treated isocentrically at a SAD of 100 cm (SSD of 90 cm) to a dose of 200 cGy midplane, two fields per day. In this case, the treatment dose per field is 100 cGy, the depth of treatment is 10 cm (one-half of the patient thickness), and the machine SAD is 100 cm. The equation we use is:

\[
N_{\text{mu}} = \frac{\text{Dose}}{C_{\text{cal}} \cdot C_{f_s} \cdot C_{\text{sem}} \cdot TMR \cdot \left( \frac{\text{SSD} + d_{\text{inner}}}{\text{SAD}_{\text{cal}}} \right)^2}.
\]
The field size yields an effective square field of 14.8 cm² for a field size factor of $C_{fs} = 1.030$ from appendix 5, table 8. The patient is treated by the SAD technique; therefore, the appropriate attenuation factor for tissue is the TMR. From appendix 5, table 7, the TMR value is 0.816. We know the calibration is performed at 100 cm SSD and, therefore, the SAD to the point of calibration is 101.5 cm. Substituting the values in the above equation, we obtain:

$$N_{\mu} = \frac{100}{1.0 \cdot 1.030 \cdot 0.816 \cdot \left( \frac{100}{101.5} \right)^2}$$

$$= 1190 \cdot 0.971$$

$$= 115.5.$$  

therefore, the $\mu$ setting is 116.

If a blocking tray is used in the beam, the tray transmission factor would be used in the denominator as $C_{att}$. If a manual calculation is performed for a wedged field, the $C_{att}$ factor would be the wedge transmission factor. The calculation equation then becomes:

$$N_{\mu} = \frac{\text{Tumor dose}}{C_{cal} \cdot C_{tis} \cdot C_{tray} \cdot C_{wedge} \cdot DD}.$$  

Calculations for $^{60}$Co beams are similar in principle to those described above except that the output is in cGy per minute and the answer is in units of time (i.e., minutes and seconds). Tables in appendix 5 provide sample beam data for several different beam energies.

**Problems**

Using the data tables in chapters 7 and 12 and appendix 5, perform the following calculations:

1. Determine the timer setting necessary for the following treatment:
   - Skin Dose = 250 cGy
   - Energy: Orthovoltage: $f_{\text{muscle}} = 0.91$
   - Machine Calibration: 82.1 R/min at the cone tip, SSD = 50 cm
   - Field Size: 2 cm $\times$ 8 cm: BSF = 1.25
   - Tissue Treated: muscle equivalent
   - Timer Error: 2 seconds (to be added)
2. Determine the μ setting necessary to deliver 100 cGy to a depth of 15 cm in the following field:
   - Energy: 4 MV
   - SSD: 80 cm
   - Field Size: 12 cm × 15 cm

3. If 100 cGy is delivered in problem 2, what is the given dose?

4. If the depth in problem 2 is changed to 10 cm, what is the μ setting?

5. What is the timer setting for delivery of 300 cGy to a depth of 6 cm in a 60Co beam with an SSD of 80 cm if the field size is 10 cm × 10 cm, the timer error is 0.01 min (to be added), and the machine output calibration is 82.1 R/min at 80 SAD?

6. What is the answer to problem 5 if the field size is not 10 cm × 10 cm but is instead blocked down from that to 5 cm × 5 cm (as in the following figure) and if the calculation is performed to deliver the dose at point P1? (This concept was covered in chapter 12.)

7. In appendix 6, table 3, locate the d_{max} for a 6 MV beam.

8. What is the answer for problem 2 if a tray with a transmission factor of 0.98 is used to support a tiny block in the field? Assume that the small block has no affect on the depth dose.

9. What is the μ setting to deliver 150 cGy to a depth of 15 cm with a 6 MV 15 cm × 20 cm beam if the tumor is at the machine isocenter (100 cm SAD) and if the machine was calibrated at 100 SSD?

10. What is the output factor (cGy/μ) for a 10 cm × 10 cm field setting at 200 cm SSD if at 100 cm SSD the output factor is 1.000 cGy/μ for the 20 MV photon beam?
BIBLIOGRAPHY


**Index**

Note: Page numbers followed by f refer to figures; page numbers followed by t refer to tables.

- absorbed dose, 83–84
  - to air, 83–84
- dose equivalent and, 89, 295
- f-factor of medium and, 84–86, 86t
- for x-rays above 3 MeV, 86–88
  See also dose
- absorption coefficient, 57, 57f, 84, 85t
- absorption edge, 50
- absorption of photons, 35, 47
- abutting fields, 147–149, 148f
  - beam splitters used with, 150
- of electrons, 208–209
- intensity-modulated radiation therapy
  - and, 173
- accelerated fractionation, 178
- acceleration, 2, 3
- accelerators. See linear accelerators
- Accredited Dosimetry Calibration Laboratory, 80, 209
- achromatic magnets, 114
- active length, of sealed source, 279, 280f, 313
- activity, of radioactive source, 286–287, 313, 360–362, 361f
- adaptive therapy, 269
- afterloading, 283–284, 288
- agreement states, 294
- air kerma, 79, 80, 81–82
- air kerma strength, 287
- ALARA, 302, 304
- alloys, 167–171, 169f. See also Cerrobend
- alpha decay, 362–363, 363f
  - alpha particles, 11
    - health effects of, 363
    - as ionizing radiation, 11, 12, 12f
    - in magnetic fields, 12, 13f
    - in proportional counter, 63, 63f
    - range in air, 363
- American Association of Physicists in Medicine (AAPM), 87, 209
- annealing, of thermoluminescent dosimeters, 72
- apparent activity, of brachytherapy source, 287
- applicators, 281, 282f, 283f
- arc therapy, 234, 235f
- area, 2
- asymmetric beam, 117f, 118
- asymmetric collimation, 150, 151f
- asymmetric jaws, 118, 171
- Atomic Energy Commission (AEC), 294
- atomic mass number (A), 10, 359
- atomic nomenclature, 359–360
- atomic number (Z), 10, 359
  - Compton effect and, 52, 53t
  - of Geiger-Mueller chamber wall, 64
  - of ionization chamber wall, 62
  - pair production and, 53
  - photoelectric effect and, 48, 50
  - of target, 29, 31
- atomic structure, 8–10, 8f, 9f
- attenuation coefficients, 45–47, 46f
  - absorption coefficient and, 57, 57f
  - linear, 36–37, 39–40, 41–42, 41t, 42t
attenuation coefficients (cont.)
mass, 41–42, 42t, 43f, 46–47, 46f, 53, 54f, 55
attenuation factors
equipment, 183–184, 184t, 187, 188, 190, 248
patient, 184–185. See also specific factors
attenuation of photon beam, 33, 34–41, 35f
defined, 34–35
interactions leading to, 47, 54f, 55, 56, 56f
transmission curves and, 36f, 37, 37f, 38f, 39
See also attenuation coefficients; filters;
half-value layer (HVL); shielding attenuators, 35, 35f. See also filters
Au-198 (gold-198), 310–311, 311t
Auger electrons, 365
automatic setup, 124

back pointers, 222
background radiation, 303
backscatter, 178
depth of maximum dose and, 178, 179f, 180, 194
backscatter factor (BSF), 178–180, 180f
beam on time and, 245
table of, 245t
tissue-air ratio and, 189, 190, 195
ballooning, of electron isodose curves, 208, 209
barrier design, 316–320, 318f, 319f
beaded trays, 146–147, 146f
beam. See electron beams; field; x-ray beams
beam arrangements. See four-field box;
four-field diamond; parallel opposed fields (POF); tangent fields
beam flatteners. See flattening filters
beam hardening, 27, 39
beam on time calculations, 243–246
beam profiles
of electron beam, 208, 208f
of photon beam, 197–199, 198f
See also flatness; flattening filters;
penumbra; symmetry
beam size. See field size
beam splitters, 15o
beam weighting, 260, 261f
beam’s-eye-view displays, 267, 267f, 268
BEIR (Committee on the Biological Effects of Ionizing Radiation), 298–299, 302
bending magnet, 112, 113f, 114
beta decay, 363–364, 365f
of cobalt-60, 128–129
beta-minus particles, 11, 363–364
brachytherapy with, 289
proportional counter used for, 63, 63f
See also electron(s)
See also positrons
binding energy, 10
bite blocks, 222, 223f
block(s)
Compton scattering and, 50, 52
custom, 167–171, 168f, 169f, 170t, 171
half-value layers of, 41, 170t
scattered radiation from, 176
block cutter, 168, 169f
block tray, 166f, 168, 170
attenuation factors for, 183, 184, 184t, 187, 248
blocking, 165–171
beam divergence and, 166f, 167, 167f, 171
in conformal therapy, 268–269
dose calculations with, 190–194, 191f, 192f
of electron field, 210, 211, 211t, 212f, 213
multileaf collimation compared to,
171, 171f
proportional relationships in, 165, 166f
body contours, 222, 224, 225f
Bohr model, 8–9, 8f
bolus, 238, 239f
bone
f-factor for, 85–86, 86t
mass attenuation coefficient of, 46, 46f
photoelectric effect in, 50
bone metastases, 312
boost fields, 252, 265
brachytherapy, 277–291
  afterloading in, 283–284, 288
  applicators for, 281, 282f, 283f, 289
  basic concept of, 278
  dosimetry of, 281, 286–288
  plaques for, 289
  radiation safety in, 283, 288, 289, 310–315
  radioactive sources for, 279, 280f, 281, 289
  radionuclides used in, 278–279, 279t, 310–312, 311t
Bragg peak, 137–138, 137f
Bragg-Gray cavity theory, 86–88, 87f
  brain lesions
    mixed field for, 256, 257f
    stereotactic radiosurgery for, 265, 266f
    temporary implants for, 289
    vertex field for, 253, 253f, 254f, 265
  breast tangents. See tangent fields
  bremsstrahlung, 20, 24–26, 25f
  attenuation of, 37, 39
  bremsstrahlung tail, 206–207, 206f
  build-up cap, 62, 189, 194
  byproduct material, 66, 294

C₂ values, 87, 88t
  calcium fluoride detectors, 71, 72f
  calibrated dosimeter, 80
  calibration
    of cobalt-60 beams, 245
    of conventional x-ray machines, 80–82, 81f, 82t, 245
    of electron beams, 209
    ionization chambers for, 64
    of survey meters, 66–67
    of thermoluminescent dosimeters, 73
  calibration factor
    from accredited laboratory, 80
    in electron dosimetry, 210
    in photon dosimetry, 181–182, 187–188, 190
  cap of ionization chamber, 61f, 62
  build-up cap, 62, 189, 194
  cathode ray tube, 19, 20f
  cavity theory, 86–88, 87f
central ray, 150, 176, 177f, 198f
Cerrobend
  for blocking electron beams, 210, 211, 211t, 212f
  for blocking photon beams, 170–171, 170t
  compensating filters made of, 240
  properties of, 170
cesium-137, 67, 310, 311t, 313–314
  chamber, 60, 60f. See also ionization chambers
  characteristic radiation, 20, 22–24, 23f, 48, 49f
  characteristic x-rays, 23, 25, 25f, 48
  in Thoraeus filter, 27–28
charged particles
  force between, 3–4, 5f, 9
  in magnetic field, 12, 13f
  masses and rest energies, 13t
  See also particulate radiation
check sources, 66–67
chromatic magnets, 114
Clarkson method, 191, 191f, 193
clinical target volume (CTV), 218, 219, 219f, 220
cobalt-60
  in brachytherapy, 310
  characteristics of, 311t
  in radiosurgery, 128
cobalt-60 machines, 128–136
  advantages and disadvantages of, 128
  collimator scatter with, 176
  depth dose with, 187t, 188, 351t
  emergency procedures for, 134, 135t
  head of, 130, 131f
  isodose curves with, 227, 227f
  penumbra with, 132–134, 133t, 134f
  quality assurance of, 134–136
  radiation safety with, 130, 133–134, 135–136, 316–321
  radiation sources in, 128–130, 129f
  source exposure mechanisms, 130
  time calculations for, 244, 245, 246, 248
  timer error with, 130–132, 132f, 245
  tissue-air ratio with, 190, 191–194, 192f, 356t
cobalt-60 machines (cont.)
  written directive for treatment with, 135–136
coherent scatter, 47–48, 47f, 54f, 56f, 57
cold spot, with abutting fields, 149
collection efficiency, of gas ionization
detector, 61, 63
collimation
  of cobalt-60 beams, 133, 134f
  of electron beams, 120, 121f, 122
isocentricity and, 163
  of neutron beams, 138–139
  of photon beams, 118
  of proton beams, 138
scattered radiation resulting from, 176
See also jaws; multileaf collimators
(MLCs)
collision interactions, of electrons with
  matter, 20–22, 21f, 22f
colpostats, 281, 282f
Committee on the Biological Effects of
  Ionizing Radiation (BEIR),
  298–299, 302
compensating filters, 238, 239f, 240. See
  also wedges
Compton scattering, 50–52, 51f
  attenuation coefficient and, 54f
backscatter factor and, 179
in film badge, 305
in ionization chambers, 62
as proportion of interactions, 56, 56f
skin sparing and, 100
computed tomography. See CT scans
computers in radiation oncology, 201,
  270
  for control of linear accelerators, 124
  for milling of customized
  compensators, 240
concrete barriers, 52, 316, 318–319, 319f
condensed air, 62
conduction band, 70, 71f
cone beam CT (CBCT), 220, 272
cones, 120, 214
conformal methods, 268–269, 268f, 270,
  270f, 272
conservation of energy, 4
constructive interference, 107
contact cones, 120, 214
continuous spectrum, 23f, 24
contouring a patient, 222, 224, 225f
controlled area, 317, 319
conventional x-ray machines. See
diagnostic imaging; orthovoltage
x-ray beams; orthovoltage x-ray
machines; superficial x-rays
conversion factors, 327–328
coordinate system, 150–151, 152f, 153f,
  154f
coplanar beams, 155, 265
coronal plane, 224, 225f
corpuscular emissions, 78, 79
cosmic rays, 12–13
couch. See table
Coulomb force, 3–4, 5f, 9
counts per minute (cpm), 67
critical structures, 219
CT scans, 220, 224, 267, 268, 272
cutie pie, 64, 65, 65f, 66t, 68
CyberKnife, 109, 273f, 274
cyclotrons, 136–137, 136f, 138
d_{max}. See depth of maximum dose (d_{max})
dead time, of Geiger–Mueller counter, 64
decay products. See radioactive decay
deep dose equivalent, 303, 305
dees, 136, 136f
de-excitation of atoms, 68
density
  of common materials, 358t
Compton effect and, 52
defined, 2
mass attenuation coefficient and, 42,
  42t
See also electron density
depth dose (DD), 184–188
with cobalt-60 machines, 187t, 188,
  351t
defined, 185–186, 186f
with electron beams, 205–207, 205f,
  206f
measurement of, 185, 185f
do of neutrons vs. photons, 138, 139f
vs. photon beam energy, 94–95, 95f, 96f, 98, 100t, 187t
source to skin distance (SSD) and,
186–187, 186f, 187t, 188, 190
tables of data, 100t, 187t, 351t–355t
tissue-air ratio and, 189–190
tumor dose and, 187–188
depth of maximum dose \( (d_{\text{max}}) \), 99f, 100–101, 101t, 176, 177f
backscatter and, 178, 179f, 180, 194
bolus and, 238
depth dose and, 185–186, 186f
for electron beams, 206
field size correction and, 180–182
oblique incidence and, 229
tissue-maximum ratio and, 194, 195f
See also maximum dose \( (D_{\text{max}}) \)
destructive interference, 107
diagnostic imaging
calibration of x-ray machines for,
80–82, 81f
Compton scatter in, 52
filtration in, 26
photoelectric effect in, 50
x-ray tubes for, 29, 30f, 31
diamond technique, 233, 233f
diffraction, 15
digitally reconstructed radiographs
(DRR), 220
diode detectors, 73–74, 74f
distance terms, 176, 177f
distribution factor, 295
divergence of x-ray beam, 33, 34, 34f
asymmetric collimation and, 150
beam splitters and, 150
blocking and, 166f, 167, 167f
depth dose and, 186, 187
independent collimators and, 150
multileaf collimation and, 171
non-midplane anatomy and, 149
See also inverse square law
diverging blocks, 167–168, 168f, 169f
dose
in air, 83–84, 178
backscatter and. See backscatter factor
(BSF)
for blocked fields, 190–194, 191f, 192f
distance relationships and, 165
distance terms and, 176–177, 177f
field size and. See field size correction
factor
in a medium, 84–86
See also absorbed dose; attenuation
factors; equivalent dose \( (H) \); maxi-
mum dose \( (D_{\text{max}}) \); tumor dose \( (TD) \)
dose build-up, 99, 99f
dose distributions. See isodose distributions
dose equivalent. See equivalent dose \( (H) \)
dose fractionation, 177–178, 278
dose profiles. See beam profiles
dose response relationships, 297–298, 297f
dose to maximum zone of intensity
(MZI), 176
dose-volume histograms (DVHs), 269, 269f, 270f
dosimeter correction factor, 209
dosimetrist, 218, 224
double plane implant, 284, 285f
drift tubes, 104, 105f
dummy brachytherapy sources, 283, 284
dynamic fields, 233–234, 234f, 235f
dynamic therapy, 201
dynamic wedge, 242, 258
ears. See horns (ears)
edges of beam, 143, 198f, 199
effective dose, 296
effective dose equivalent, 296
effective energy, of cobalt-60, 128
effective TAR method, 236–238, 237f
effective wedge angles, 240, 242, 258
efficiency, of ion chamber, 61, 63
elastic collisions, 20–21, 21f
electric fields, of electromagnetic waves, 15, 16f
electromagnetic energy, 15, 17
electromagnetic radiation, 14–17, 16f
interference of, 107
spectrum of, 14–15, 14f
See also gamma rays; X-rays
electrometers, 79
electron(s)
atomic structure and, 8–10, 8f, 9f
electrostatic force on, 3–4, 5f, 9
interaction with matter.
See bremsstrahlung; characteristic radiation
as ionizing radiation, 11, 12, 12f
in magnetic fields, 12, 13f
secondary, 12, 79, 99, 99f
electron beams, 203–215
broadening of raw beam, 118–120, 119f
calibration of, 209
collimation of, 120, 121f, 122
depth dose with, 205–207, 205f, 206f
energy of electrons in, 203–205, 204f
energy to treat specific depth, 210, 210f
inverse square law with, 211, 214
isodose curves for, 196, 197f, 208, 208f, 213, 213f
mean beam energy at surface, 207
mixed with photon beams, 253, 256, 257f
monitor units with, 209–211
range of, 204–205, 207, 207t
raw, 114f, 115
tissue inhomogeneities and, 213–214, 213f
electron capture, 365, 366f
electron cones, 120, 121f, 214
electron contamination, 176
from penumbra trimmers, 133
electron density
Compton effect and, 52
of various materials, 53t
electron equilibrium, 62, 100–101, 178, 179f
electron gun, 106
electron volts (eV), 4, 11, 11t
electronic portal imaging, 220, 221
electrostatic force, 3–4, 5f, 9
electrostatic potential energy, 4
electrostatic unit of charge (esu), 78
elements
characteristics of, 367–370
periodic chart of, 372–373
energy, 3–4, 5f
absorbed dose and, 83–84
kerma and, 79–80
of a photon, 17
units of, 3–4, 11, 11t
energy spectrum. See spectrum
equal beam weighting, 260
equipment attenuation factors, 183–184, 184t, 187, 188, 190, 248
equivalent dose (H), 88–89, 295–296
effective, 296
maximum permissible, 302–303, 303t, 304
equivalent energy of beam, 40–41
equivalent square field (ESF), 182–183, 183t
monitor unit calculation and, 248
time calculation and, 244, 244f, 246
erythema dose, 78
excitation of electron, 9, 21, 22f, 68, 69f
exit dose, 101, 176–177
exponential function. See semi-logarithmic graph
exposure
roentgen unit of, 78–79, 85
safety with radionuclides and, 313
exposure rate, 67–68, 79
of brachytherapy source, 286–287
eye lesions
proton therapy for, 138
strontium-90-yttrium-90 sealed source for, 289, 312
f-factor, 84–86, 86t, 245
fiducial markers, 272
fiducial plates, 146–147
field, coordinate system for, 150–151, 152f, 153f, 154f
field lights. See light field
field size
  asymmetric collimation and, 150
collimator scatter and, 176
defined, 143, 176, 177f
depth of maximum dose and, 176
flatness and, 199
intensity-modulated radiation therapy
  and, 173
isocenter and, 157, 159, 161f
magnified image of, 144–147, 145f
patient attenuation factors and,
  184–185
selection of, 220
source to skin distance and, 143–144,
  143f, 164–165
tissue-air ratio and, 191, 192f
  See also equivalent square field (ESF)
field size correction factor
  for electron beam, 210
  for photon beam, 181–182, 181f,
  187–188, 190, 358t
field weighting, 260, 261f
field-within-a-field, 252, 252f
film, magnification factor of, 144–146,
  145f
film badge, 304–305
filters
  compensating, 238, 239f, 240
  with conventional x-ray machines,
  26–28, 27f, 82, 82t
  for electron contamination, 176
  See also attenuation of photon beam;
  flattening filters; wedges
flatness
  of electron beam, 122
  of photon beam, 116, 118, 120,
  198–199, 198f
  quality assurance checks of, 125–126,
  125f
flattening filters, 115, 116f, 117f, 118, 120
horn region and, 199
photonuclear interaction in, 56
scatter from, 176
fluorescence, 68
focal spot size, 96
forces, 3
  electrostatic, 3–4, 5f, 9
four-field box, 155, 156f, 232, 232f, 265
four-field diamond, 233, 233f
fractional depth dose (FDD), 186
fractionation, 177–178, 278
free electrons, 50, 52
frequency, 16–17
fused images, 220

Gamma Knife, 128
gamma rays, 11, 14, 14f
  from cobalt-60 beta decay, 129
  from radium, 278, 362–363, 363f
gamma-n interaction. See photonuclear interaction
gantry angle, 154, 155f
gantry angle indicator, 221
gantry rotations, and isocentricity, 163
gaps, in abutting fields, 147, 148f, 209
gas ionization detectors, 60–65
  appropriate uses of, 64–65, 65f, 66t
  basic mechanisms of, 60–61, 60f, 61f
  collection efficiency of, 61, 63
  moderated, as neutron dosimeters, 69
  operational regions of, 61, 62f
  as survey meters, 65–68
  See also Geiger (G–M) counters;
  ionization chambers; proportional counters
gated radiation therapy, 272–274
Geiger (G–M) counters, 60, 63–65, 65f, 66t
  as survey meters, 65–68, 67f
Geiger–Mueller region, 62f, 63
government regulations, 294, 320, 321.
  See also Nuclear Regulatory Commission (NRC)
gold-198 (Au-198), 310–311, 311t
gold-198 (Au–198), 310–311, 311t
government regulations, 294, 320, 321.
  See also Nuclear Regulatory Commission (NRC)
gray (Gy), 79, 80, 83–84
  conventional x-ray machine calibration
  in, 80–82, 82t
equivalent dose and, 295
  roentgen to cGy conversion factor,
  85–86, 86t, 245
Grenz rays, 27, 86t
gross tumor volume (GTV), 218, 219f
ground state, 9
gynecological malignancies
  brachytherapy applicators for, 281, 282f, 283f
  cesium-137 for, 310

H. See equivalent dose (H)
half-life, 360–362
half-value layer (HVL), 36, 38f, 39–41
  of shielding, 307, 308, 313–314
  values for common beams, 40t
  values for radionuclides, 311t
hardening of beam, 27, 39
head holders, 222
head leakage. See leakage radiation
heat energy, in x-ray tubes, 4, 31
heavy particle therapy, 14, 137–139, 139t
hinge angle, 242f, 243
homogeneity coefficient (HC), 39, 40t
homogeneous beam, 37, 39–40
horns (ears)
  of electron beam, 208
  of photon beam, 196f, 198f, 199
hot spots
  with abutting fields, 147, 148, 208
  beam weighting and, 260, 261f
  with breast tangents, 240, 257f, 258, 258f, 259f
  with oblique surfaces, 240, 242f, 243f
  of three-field wedged plan, 254
hydrogen atom, 10
hyperfractionation, 178

image-guided radiation therapy (IGRT), 272, 273f
immobilization devices, 222, 223f
implant. See brachytherapy
implant gun. See seed gun
incident dose (ID), 176, 177f, 186, 188.
  See also maximum dose (Dmax)
independent collimators, 118, 119
inelastic collisions, 20–21, 21f
inertia, 12
intensity of x-ray beam
  compared to dose, 99f, 100
  defined, 33
  divergence and, 33, 34, 34f
  See also attenuation of photon beam
intensity-modulated radiation therapy
  (IMRT), 173, 270–272, 271f
  with charged particle beams, 138
interference of waves, 107
interfield distances (IFD), 224, 225f
internal conversion, 365
International Commission on Radiological Protection (ICRP), 294, 296, 298
interstitial implants, 281
  after teletherapy, 284
  permanent, 284–285, 286f
  tumor volume and, 284, 285f
  See also brachytherapy
intracavitary implants, 281. See also brachytherapy
inventory, of brachytherapy sources, 314
inverse square law, 34, 34f, 165
  for brachytherapy source, 287
  depth dose and, 186
  electron beams and, 211, 214
  output calculation and, 181–182
  radiation protection and, 307, 309
  tissue-air ratio and, 189, 190
  tissue-maximum ratio and, 194
  See also divergence of photon beam
iodine-125, 311t, 365
iodine-125 implants, 284, 285, 286f, 310, 311
  for brain tumors, 289
iodine-131
  characteristics of, 311t, 359
  radiation safety with, 311–312, 314–315
ion pairs, 22
  in gas ionization detector, 60, 60f
ion recombination, 61, 62f
ionization, 9, 10, 22, 22f
ionization chamber region, 61, 62f
ionization chambers, 60–63, 60f
  appropriate uses of, 64, 66t
  Bragg-Gray cavity theory and, 86–87
  electrometers associated with, 79
  electron beam measurements with, 209
  materials used in, 62
  operational region of, 61, 62f
  portable (cutie pie), 64, 65, 65f, 66t, 68
  pressure dependence of, 80–81
  sensitivity of, 80–81
  temperature dependence of, 80–81
  thimble chamber, 61f, 62, 65f
  See also monitor ionization chamber
ionization current, 60
ionization detectors. See Geiger
  (G-M) counters; ionization chambers; proportional counters
ionizing radiation, 7–8, 11, 12–13
iridium-192, 279, 280f, 284, 285f, 289
  characteristics of, 311t
  occupational exposure to, 310
irises, 106, 107f
irradiated volume, 218, 219f
irregularly shaped fields. See block(s); blocking
isocenter
  defined, 97, 157, 158f
  distance from source, 111, 112f, 113f,
  157, 159
field size and, 157, 159, 161f
lasers pointing to, 163, 164f, 221–222
normalization to, 263–264, 264f, 264t
isocentric machine, 97, 98f
isocentric technique, 159, 160f
  in intensity-modulated radiation
  therapy, 173
  with parallel opposed fields, 159, 161f,
  162f, 163–164
pinning in, 159–160, 163, 163f, 164f
rotation of equipment for, 163–164
isodose curves, 196–197, 196f, 197f
  normalization to, 262–263, 263f
isodose distributions, 226–227, 226f, 227f
  of breast tangents, 256, 257f, 258,
  258f, 259f
  of electron beams, 196, 197f, 208,
  208f, 213–214, 213f
  of four-field box, 232, 232f
  of four-field diamond, 233, 233f
  of mixed beams, 255f, 257f
  normalization of, 260, 262–264, 262f,
  263f, 264f, 264t
with oblique incidence, 227–228,
  228t, 229f, 240
  with rotational technique, 233–234,
  234f, 235f
summatated, 229–230, 230f
three-field, 231f, 232
  of vertex field, 253, 254f
  wedges and, 240, 241f, 242f, 243f
isodose shift
  oblique incidence and, 228, 228f, 229f
  tissue inhomogeneities and, 236f, 238
isodose summations, 229–230, 230f
isometric transition, 365–366, 366f
isotopes, 359–360
jaws, 112f, 113f, 118, 120, 121f
  compared to multileaf collimation,
  171, 172f
as dynamic wedge, 242, 258
scattered radiation from, 176, 180
  See also collimation
joule (J), 3–4, 11
Kelvin (K), 80, 81
kerma, 79–80. See also air kerma
kilo electron volt (keV), 11t
kinetic energy (KE), 4. See also air kerma;
kerma
klystrons, 109, 110f, 111
kVp, 82, 82t
lasers, 163, 164f, 221–222
late effects, of radiation exposure,
  296–297
latent period, for tumor formation, 297
lattice, crystal, 70, 70f
lead
  Cerrobend compared to, 170t, 171
  mass attenuation coefficient of, 46, 46f
lead blocks
  with electron beams, 210
  with photon beams, 170t, 171
lead cutout, 244, 244f
leakage radiation, 316, 319–320, 321
length, units of, 2, 3t
light field, 221
  blocking and, 166f, 167, 167f
line spectrum, 23–24, 23f
  of cobalt–60 beta decay, 128
linear accelerators, 103–126
  angular spread of beam, 29
  basic principle of, 104, 105f
  with bent-beam design, 112, 113f, 114
  on board imagers of, 272
  control console of, 124
  depth dose tables for, 352t–355t
  dose to therapist working with, 320–321
  dual energy, 254
  early development of, 104
  helical technology for, 123
  initial testing of, 320
  penumbra with, 132–133, 133t
  power sources of, 109, 110f, 111
  quality assurance for, 124–126, 125t
  radiation safety with, 316–321, 318f, 319f
  radioactivity induced in accessories of, 56, 320–321
  safety interlocks of, 122, 124, 125–126, 125t
  state regulation of, 294
  with straight-through design, 111–112, 112f
  target of, 30, 115, 116f
  tissue-maximum ratio, table of, 357t
  waveguides of, 105–109, 105f, 107f, 108f, 109f
See also isocenter; isocentric technique; megavoltage x-ray beams
linear attenuation coefficient, 36–37, 39–40, 41–42, 41t, 42t
linear dose response model, 297–298, 297f, 299, 299f
linear energy transfer (LET), 12
  of alpha particles, 63
  of heavy particle beams, 137
  quality factor and, 89–90, 89t
linear-quadratic model, 298, 299f
lithium fluoride detectors, 69, 71–72, 72f
liver metastases, yttrium-90 microspheres for, 312–313
localization. See simulation (localization)
low dose rate (LDR) brachytherapy, 288
lung tissue, 42
machine output, 245
magnet, bending, 112, 113f, 114
magnetic fields
  charged particles in, 12, 13f
  of electromagnetic waves, 15, 16f
magnetrons, 109, 110f, 111
magnification, 144–147
  of non-midplane anatomy, 149–150
mammography, photoelectric effect in, 50
Manchester System, 281
mass
  acceleration and, 3
  of subatomic particles, 12, 13t
  units of, 2, 3t
mass attenuation coefficient, 41–42, 42t, 43f, 46–47, 46f
  for four major interactions, 54f, 55
  pair production and, 53
mass density. See density
mass energy absorption coefficient, 57, 57f, 84, 85t
mass number (A), 10, 359
matter, 1–2
maximum dose (Dmax), 100, 176
  normalization to, 262, 262f
See also depth of maximum dose (dmax); incident dose (ID)
maximum energy, in photon beam, permissible exposure and, 317
maximum permissible doses (MPDs), 302–304, 303t
maximum value in target volume, 262
Mayneord’s factor, 188
medical and dental x-ray exposure, 300t, 301–302, 303
medical event, with cobalt-60 machine, 136
mega electron volt (MeV), 11t
megavoltage x-ray beams, 28
advantages of, 98–101
characterization of, 41
Compton effect with, 52
direction of, 29, 29f, 30, 30f
disadvantages of, 101
isodose curves for, 227, 227f
roentgen to cGy conversion factor for, 86t
See also cobalt-60 machines; linear accelerators
megavoltage x-ray tubes, heat production in, 31
metric system, 2, 3t
mg-radium equivalent, 279, 286, 288
midline, 149, 149f
midplane, 149, 149f
milligram-hour of radium, 281, 286
mirror images, in isocentric treatment, 163–164
mixed beams, 253–256, 255f, 256f, 257f
mmHg, 80
monitor ionization chamber, 120, 122–123, 123f
backscattering to, 180
quality assurance checks of, 125t, 126
scattered radiation from, 176
monitor units, 244
with electron beams, 209–211
field size and, 180, 182
monitor chamber and, 122
tumor dose and, 187–188, 190, 194, 195, 247–248
monoenergetic beam, 37, 39
Monte Carlo algorithms, 214
MOSFET detectors, 74
motion, patient
gating and, 272–274
positioning devices and, 222, 223f
mouthpiece, custom, 222, 223f
moving (dynamic) fields, 233–234, 234f, 235f
multileaf collimators (MLCs), 118, 171, 171f, 172f, 173, 270–271
leakage radiation with, 320
with proton beams, 138
muscle
attenuation and absorption coefficients for, 57, 57f
f-factor for, 85–86, 86t
National Council on Radiation Protection and Measurements (NCRP), 294, 296, 305, 317
negative ion, 10, 22
negatron, 53
neutron beams, 14, 138–139, 139t
neutron dosimeters, 69
neutrons, 10, 11, 13t
from photonuclear interaction, 55–56, 55f, 320
newton (N), 3
non-contact cones, 120, 214
non-coplanar beams, 265, 265f, 266f
non-midplane structures, 149
normalization
of depth dose, 185–186
of dose distribution, 260, 262–264, 262f, 263f, 264f
Nuclear Regulatory Commission (NRC), 294, 304, 305
brachytherapy requirements of, 314–315
cobalt-60 machines and, 134–136, 320
iodine-131 and, 311
survey meters and, 66–67
nuclides, 10
nucleus, 8–9, 8f, 10
isomeric transition of, 365–366, 366f

oblique incidence, 227–228, 228f, 229f, 240
occupancy factor, 317–318
occupational dose
  internal, 303–304
  measurement of, 295–296
  recommended limits, 296, 302–304, 303t
  See also radiation safety
occupational radiation risk, 298–301
off-axis points, 176
off-axis ratio (OAR), 199
off-center ratio (OCR), 199
off-cord boost field, 151f
on board imagers (OBI), 272
orthogonal images, 151, 154f, 220
  for brachytherapy, 283
orthovoltage x-ray beams
  Compton effect with, 52
  filtration of, 27–28, 27f, 82, 82t
  isodose curves for, 227, 227f
  transmission curves of, 38f
  tube design for, 29–30
orthovoltage x-ray machines
  calibration of, 80–82, 81f, 82t
  disadvantages of, 94–97
  leakage radiation with, 320
  time calculation for, 244–246
  timer error with, 130–132, 132f
output
  of conventional x-ray units, 82, 82t
  field size and, 180–182, 181f
  machine, 245
over-responding G–M tube, 64
ovoids, 281, 282f, 283f

pair annihilation, 54f, 55, 365
pair production, 53, 54f, 56, 56f
palladium-103 (Pd-103), 310–311, 311t
parallel opposed fields (POF), 155, 156f
  isocenter position for, 159, 161f, 162f
  isodose distributions of, 229–230, 230f, 231–232
  misaligned, 258, 259f
  monitor unit calculation for, 247–248
rotation of equipment for,
  163–164
  tangential, 155, 157f
  unequally weighted, 260, 261f
particulate radiation, 12–14, 13t
  dose equivalent of, 88–90
  See also charged particles
pascal, 80
past pointing, 235, 235f
Paterson–Parker technique, 288
patient alignment devices, 221–222
patient attenuation factors, 184–185. See
  also specific factors
patient positioning aids, 222, 223f
patient support assembly (PSA). See table
peak scatter factor (PSF). See backscatter
  factor (BSF)
pencil electron beam, 114f, 115
penumbra, 15
  with cobalt-60 machines, 132–134, 133t, 134f
  defined, 197, 198f
  geometric, 95–96, 97f
  multileaf collimation and, 171, 171f
  physical, 96
penumbra trimmers, 132–133, 134f
percent depth dose (PDD)
  defined, 186
  of neutrons vs. photons, 138, 139t
  vs. photon beam energy, 94–95, 95f, 96f, 100t
  See also depth dose (DD)
period, of a wave, 16
permanent implants, 284–285, 286f
radiation safety with, 289
Se also brachytherapy
personnel monitoring, 304–306, 321
phantom attenuation. See patient attenuation
  factors
phosphorescence, 68
phosphorus-32, 311t, 312, 315, 364, 365f
photodisintegration. See photonuclear
  interaction
photoelectric effect, 48–50, 49f, 54f
  absorption coefficient and, 57
  in film badge, 305
  as proportion of interactions, 56, 56f
photon beams. See x-ray beams
photon contamination, 206–207
photon nuclear interaction, 55–56, 55f, 56f
dose to therapist and, 320–321
radiation survey and, 320
physical penumbra, 96
pinning, 159–160, 163, 163f, 164f, 173
π-mesons, 13t, 14
planes, description of, 150–154, 152f, 153f, 154f
planning target volume (PTV), 218, 219f, 224
plaques, 289
polarization voltage, 61, 62f
polyenergetic beam, 38f, 39
portal images, 220, 221
contrast in, 52
magnification of, 144
positioning of patient aids for, 222, 223f
image-guided, 272, 273f
during simulation, 220
positive ion, 10, 22
positrons, 10, 11, 13
amplification of, 54f, 55, 365
in pair production, 53, 54f
potential energy (PE), 4
practical range, 207
pre-annealing, of thermoluminescent
dosimeters, 72
pre-calculated system of dosimetry, 288
pregnancy
occupational dose limits, 303t, 304
radiation risk in, 301–302
of visitor to patient, 314
prescribed dose, 218. See also tumor dose
(TD)
prescription, for cobalt–60 treatment, 135–136
primary barrier, 316, 318–319
primary dose, 179
primary radiation, 178–179, 191, 316
principal quantum numbers, 9
probe, of gas ionization detector, 60
profiles. See beam profiles
proportional counter region, 62f, 63
proportional counters, 60, 63, 63f, 64, 66t
prostate cancer
conformal treatment of, 268f, 269, 270f
four-field box for, 232
seeds for, 285, 286f, 311
three-dimensional treatment planning
for, 267f, 268f
proton beams, 14, 136–137, 136f, 138
protons, 10, 11, 13t
protractor, 221
quality assurance (QA)
of cobalt–60 machines, 134–136
for intensity-modulated radiation
therapy, 272
laser alignment in, 222
of linear accelerators, 124–126, 125t
quality factor (Q), 89–90, 89t, 295
quenching agents, 64
Quimby technique, 288
rad, 83–84, 295. See also absorbed dose
roentgen to rad conversion factor,
85–86, 245
radiation, defined, 7
radiation detectors
diode detectors, 73–74, 74f
introduction to, 59–60
MOSFET detectors, 74
neutron dosimeters, 69
scintillation detectors, 68, 69f
thermoluminescent dosimeters, 69–73, 70f, 71f, 72f, 73f, 305
See also gas ionization detectors
radiation oncologist, 218, 220, 224
radiation risk, 296–302
compared to other risks, 299–301, 300t
dose response models, 297–299, 297f, 299f
late effects, 296–297
occupational, 298–301
radiation risk (cont.)
of in utero exposure, 301–302
radiation safety, 293–324
  in brachytherapy, 283, 288, 289, 310–315
  cardinal principles of, 306–309, 309f
  with cobalt-60 machines, 130, 133–134, 135–136, 135t, 316–321
detectors used for, 65, 66t, 69, 70, 71–72, 72f
  for general public, 303t, 304
  government regulations for, 294, 320, 321. See also Nuclear Regulatory Commission (NRC)
  with linear accelerators, 316–321, 318f, 319f
  maximum permissible doses, 302–304, 303t
  occupational dose measurements in, 295–296
  personnel monitoring, 304–306, 321
  with radioactive materials, 310–315
  signs used in, 314, 321, 322f
radiation safety officer (RSO)
cobalt-60 machine and, 130, 134, 135t
personnel monitoring and, 306, 321
radiation survey
  of linear accelerator, 320
  using instruments for, 65–68
radiation weighting factor, 295, 296
radiative interactions. See bremsstrahlung
radioactive decay, 11, 360–362, 361f
  processes in, 362–366, 363f, 365f, 366f
  radioactive materials. See radionuclides
radioactive waste, 315
radionuclide teletherapy. See cobalt-60 machines
radionuclides
  accelerator-produced, 294
  as byproduct material, 294
  commonly used, 278–279, 279t, 310–312, 311t
decay of, 360–366, 361f
nomenclature for, 359–360
radiation safety with, 310–315
  spills of, 315
  radiosurgery, with Gamma Knife, 128
  radium-226, 278, 280f, 310, 311t
  alpha decay of, 362–363, 363f
  milligram-hour of, 281, 286
  state regulation of, 294
  radium equivalent, 279, 286, 288
  radon gas, 310, 362, 363
  ram tables, 112
  raw electron beam, 114f, 115
  recordable event, with 60Co machine, 136
  reduced fields, 252
  reflection target, 29, 30f, 31
  rem, 89, 295
  remote afterloading, 288
  rest energy, of subatomic particles, 12, 13t
  ring badge, 305, 321
  roentgen (R), 78–79
  absorbed dose and, 83
  calibration in, 80
  roentgen to cGy (or rad) conversion factor, 85–86, 86t, 245
  rotational technique, 199–201, 200f, 200t, 233–234, 234f, 235f
SAD technique, 159, 160f
safety. See radiation safety
safety interlocks, of linear accelerator, 122, 124, 125–126, 125t
sagittal plane, 224, 225f
samarium-153, 312
satellite collimators, 133, 134f
scanning of beam
  with electrons, 120, 121f, 122
  with heavy particles, 138
scatter-air ratio (SAR), 191–194, 192f
scattered dose, 179
scattered radiation
  attenuation of beam and, 35, 47, 57
  coherent, 47–48, 47f, 54f, 56f, 57
  from collimation system, 176
  field size correction and, 180
  from patient or phantom, 178–179
  protection from, 52, 316, 319, 320
See also backscatter; Compton scattering
scattering foils, 119–120, 119f, 122
  for proton beams, 138
scintillation detectors, 68, 69f
sealed sources, 279, 280f
secondary barrier, 316, 318, 319–320
secondary electrons, 12, 79
doise build-up and, 99, 99f
secondary ionization events, 62–63
seed gun, 285, 286f, 310
semi-logarithmic graph
  of beam attenuation, 37, 37f, 38f, 39
  of radioactive decay, 360, 361f
separations, of body contour, 224
shadow tray. See block tray
shells, of Bohr atom, 8–9, 8f, 9f
shielding, 307–309, 309f, 316–320, 318f, 319f
  Compton scattering and, 50, 52
  for gamma-emitting radionuclides, 313–314
  See also block(s)
shrinking fields, 252
SI system of units, 2
  prefixes in, 325–326
side-coupled standing waveguide accelerator, 109f
sievert (Sv), 89, 295
sigmoidal dose response relationships, 297, 297f
similar triangles, 142–144, 142f, 165
simulation (localization), 220
  body contour and, 222, 224
  for brachytherapy, 283
  Compton scatter in, 52
single plane implant, 284, 285f
skin dose, measurement of, 72, 73f
skin erythema dose, 78
skin gaps, with abutting fields, 147–148, 148f
skin sparing, 98–99, 99f, 100, 101
  collimator scatter and, 176
  electron beams and, 206
  oblique incidence and, 229
  tissue compensation and, 238, 240
skip arc therapy, 233
source to axis distance (SAD), 111, 112f, 113f, 176, 177f
  approach based on, 159, 160f
  film image and, 145–146, 145f
source to collimator distance (SCD), 96
source to diaphragm distance (SDD), 96, 97f
source to film distance (SFD), 145–146, 145f
  custom blocks and, 168, 169f
source to object distance (SOD), 145–146
source to skin distance (SSD), 96, 97, 97f, 176, 177f
  approach based on, 159–160, 160f
  blocked dimensions and, 165
  depth dose and, 186–187, 186f, 187t, 188, 190
electron beam intensity and, 210–211, 214
  field size and, 143–144, 143f, 164–165
sources
  brachytherapy, 279, 280f, 281, 289
  in cobalt–60 machines, 128–130, 129f
  spatial dispersion of beam, 114
specific gamma ray constant, 279t, 286–287, 313
specific ionization, 12
spectrum
  of characteristic radiation, 23, 23f
  electromagnetic, 14–15, 14f
  x-ray, 25–26, 25f
speed of light, 16
spills of radioactive materials, 315
SSD technique, 159–160, 160f
standing wave accelerator, 106–107, 108f, 109, 109f
state regulations, 294, 320, 321
stationary (fixed beam) treatment, 230–233, 230f, 231f, 232f, 233f
stereotactic radiosurgery, 118, 265, 266f
strong nuclear force, 10
strontium-89, 311t, 312
strontium-90–yttrium–90 sealed source, 289, 312
Styrofoam block and mold, 168, 169f, 170
subatomic particles, 10–11, 13–14, 13t
summated distribution, 229–230, 230f
summated percentage, 229
superficial x-rays, 27
calibration of machines for, 80–82, 81f
roentgen to cGy conversion factor for, 86t
timer error with, 130–132, 132f
tube design for, 29–30, 31
survey. See radiation survey
symbols, 325–326
symmetry
of electron beam, 122
of photon beam, 117f, 118, 197–198, 198f, 199
quality assurance checks of, 125–126, 125t
synchrocyclotron, 137
synchrotron, 137
table, 111–112, 112f
attenuation factors for, 183, 184
rotation of, 163–164
shift of, 160, 163, 163f, 164f
tandem, 281, 282f, 283f
tangent fields, 155, 157f
dose distributions with, 240, 256, 257f, 258, 258f, 259f
pins and shifts with, 163, 163f, 164f
target, x-ray, 29–31, 30f
heat production in, 31
of linear accelerator, 30, 115, 116f
target to film distance (TFD), 168
target volume
clinical, 218, 219, 219f, 220
planning, 218, 219f, 224
Task Group 51 protocol, 87, 209
tattoos, 221
technetium-99m, 365–366, 366f
teletherapy, 278
temporary implants, 281. See also brachytherapy
tenth-value layer (TVL), 307–309, 309f
thermoluminescence, 70, 71f
thermoluminescent dosimeters (TLDs), 69–73, 70f, 71f, 72f, 73f
for personnel monitoring, 305
standard procedure with, 72–73
thick target, 30
thick transmission target, 30
thimble chamber, 61f, 62, 65f
Thomson scatter. See coherent scatter
Thoraeus filter, 27–28, 27f
three-dimensional treatment planning (3-D RTP), 267–269, 267f, 268f
three-field isodose distribution, 231f, 232
thyroid treatment
iodine-131 for, 311–312
worker safety in, 315
time, in radiation protection, 306, 308–309
timer error (TE), 130–132, 132f, 245–246
timer settings, 244–246, 248
tissue compensation, 238–240, 239f
tissue inhomogeneities, 228, 235–238, 236t, 237f
with electron beams, 213–214, 213f
tissue-air ratio (TAR), 184–185, 188–194, 189f, 192f
in rotational technique, 199–201, 200t
table of, for cobalt-60, 356t
tissue-maximum ratio (TMR), 184–185, 194–195, 195f
table of, for 6 MV beam, 357t
tissue-phantom ratio (TPR), 194
tissues
attenuation by, 42
Compton scatter in, 52
toe, of wedge, 240, 241f
tomotherapy, 123
torr, 80
total effective dose equivalent (TEDE), 303
total length, of sealed source, 279, 280f
transmission factor, in barrier design, 317–318, 319f
transmission of photon beam, 35, 36f, 37, 37f, 38f, 39, 47
transmission target, 30–31, 30f
transverse plane, 224, 225f
traps, in thermoluminescent crystal, 70, 71f, 72
travel time correction. See timer error (TE)
traveling wave accelerator, 105f, 106

treated volume (TV), 218, 219f
treatment planning
aims of, 218–219
beam on time calculations, 243–246
components of, 220–221
computers in, 201
documentation of, 219, 221
for electron beams, 213–214, 213f
ersors in, 224
gating in, 272–274
imaging in, 220, 221
for intensity-modulated therapy, 173
monitor unit calculations, 244, 247–248
orthogonal images in, 151, 154f, 220
three-dimensional, 267–269, 267f, 268f
tissue inhomogeneities and, 213–214, 213f, 228, 235–238, 236f, 237f
volume definitions in, 218, 219f
See also isodose distributions; simulation (localization); tumor dose (TD)
triangulation, 163, 164f
trimmer bars, 133, 134f
tumor dose (TD), 187–188, 190, 194, 195, 218, 247–248
tumor volume, 218, 219, 219f
dose-volume histograms for, 269, 269f, 270f
interstitial implants and, 284, 285f

uncontrolled area, 317, 318, 319
under-responding G–M tube, 64
United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR), 298
United States Nuclear Regulatory Commission. See Nuclear Regulatory Commission (NRC)
units, 327–329
for mass, length, and time, 2, 3t
for radiation. See gray (Gy); rad; rem; roentgen (R)
universal wedge, 240
use factor, 317–318

valence band, 70, 71f
velocity, 2, 4
verification of treatment, 221
vertex field, 253, 253f, 254f, 265
virtual wedge, 242
visualization, 220
volume, 2. See also target volume; tumor volume

volume implant, 284

water
Compton scatter in, 52, 56, 56f
f-factor for, 85–86, 86t
mass attenuation coefficient of, 46, 46f, 54f, 55
photon interactions with, 56, 56f
water equivalent path length, 236–238
water phantom, for depth dose measurement, 185, 185f
waveguides, 105–109, 105f, 107f, 108f, 109f
wavelength, 16–17
wave–particle duality, 15
wedge angle, 240, 242
effective, 240, 242, 258
wedge pairs, 242f, 243
wedges, 240–243, 241f, 242f, 243f
flipped inadvertently, 258, 259f
monitor unit calculation with, 248
scattered radiation from, 176
weighting of beams, 260, 261f
whole body badge, 305–306
whole body dose, 295–296, 321
wipe tests, of cobalt-60 sources, 130
work, 3, 4
workload, 316–318
written directive, for cobalt-60 treatment, 135–136

x-ray beams
direction of, 28–30, 28f, 29f, 30f
edges of, 143, 198f, 199
x-ray beams (cont.)
  intensity of, 33, 34, 34f, 99f, 100
  target and, 29–31, 30f, 115, 116f
See also beam profiles; collimation;
  divergence of x-ray beam; megavoltage x-ray beams; orthovoltage
x-ray beams
x-ray tail, 206–207, 206f
x-ray tubes
  conventional x-ray output of, 82, 82t
  diagnostic, 29, 30f, 31
  energy changes in, 4
  heating characteristics of, 4, 31
  targets of, 29–31, 30f, 115, 116f

x-rays, 14, 14f, 19–20
  energy range of, in radiation therapy, 11
  spectrum of, 25–26, 25f

yttrium-90
  characteristics of, 311t
  as microspheres, 312–313
  with strontium-90 in sealed source, 289, 312

Z. See atomic number (Z)